OTC Drug Office Take Two: FDA To Elevate Division Through CDER Revamp
This article was originally published in The Tan Sheet
Executive Summary
A proposed reorganization of the Center for Drug Evaluation & Research Office of New Drugs would re-elevate the Division of OTC Drugs to office status